Skip to main content
. Author manuscript; available in PMC: 2014 Jan 27.
Published in final edited form as: Am J Gastroenterol. 2011 Sep 20;107(1):64–74. doi: 10.1038/ajg.2011.312

Table 2. Percent of patients with biomarker elevations during months 13- 48*.

Biomarker Elevation, % (N=855)
AFP ≥20 ng/ml 28.3%
AFP ≥50 ng/ml 13.0%
AFP ≥200 ng/ml 3.0%
AFP ≥20 & 2× mean prev yr, % 16.8%
AFP L3% ≥10%, % 9.6%
AFP ≥20 & AFP L3% ≥10%, % 5.3%
DCP ≥40 mAU/mL, % elevated 70.5%
DCP ≥90 mAU/mL, % elevated 28.0%
DCP ≥150 mAU/mL, % elevated 16.1%
DCP ≥90 & 2× mean prev yr, % 25.0%
AFP ≥20 & DCP ≥90, % 10.9%
AFP ≥20 & DCP ≥90 & AFP L3% ≥10%, % 3.0%
*

Percent of patients, cases and controls combined, with a biomarker above the specified limits at any one of the 12 study visits from month 13 to month 48 (0.5 to 3.5 years after randomization).